Cargando…

Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer

BACKGROUND: New approaches to ovarian cancer are needed to improve survival. Wilms’ tumour 1 (WT1) is a tumour-associated antigen expressed in many ovarian cancers. P53 is also often altered. The clinical significance of the combined expression of these two transcription factors has not been studied...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carter, Julia H., Deddens, James A., Mueller, Gretchen, Lewis, Thomas G., Dooley, Mariah K., Robillard, Michelle C., Frydl, Molly, Duvall, Lydia, Pemberton, Jackson O., Douglass, Larry E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134086/ https://www.ncbi.nlm.nih.gov/pubmed/30057405 http://dx.doi.org/10.1038/s41416-018-0191-x

Ejemplares similares

Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma
por: Carter, Julia H, et al.
Publicado: (2016)

WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis
por: Sallum, Luis Felipe, et al.
Publicado: (2018)

WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study
por: Netinatsunthorn, Wirote, et al.
Publicado: (2006)

Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma
por: Andersson, Charlotta, et al.
Publicado: (2014)

The -KTS splice variant of WT1 is essential for ovarian determination in mice
por: Gregoire, Elodie P, et al.
Publicado: (2023)

Prognostic significance of WT1 expression in soft tissue sarcoma
por: Kim, Ahrong, et al.
Publicado: (2014)

Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells
por: Blagosklonny, Mikhail V.
Publicado: (2012)

WT and A53T α-Synuclein Systems: Melting Diagram and Its New Interpretation
por: Bokor, Mónika, et al.
Publicado: (2020)

WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients
por: Koczkodaj, Dorota, et al.
Publicado: (2022)

Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile
por: Brown, Kate, et al.
Publicado: (2023)

PRMT5 regulates ovarian follicle development by facilitating Wt1 translation
por: Chen, Min, et al.
Publicado: (2021)

Autophagy regulates differentiation of ovarian granulosa cells through degradation of WT1
por: Shao, Tong, et al.
Publicado: (2022)

Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation.
por: Rizzo, M. G., et al.
Publicado: (1998)

lncRNA WT1-AS is upregulated in osteoporosis and regulates the apoptosis of osteoblasts by interacting with p53
por: Wang, Chaoqun, et al.
Publicado: (2021)

TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts
por: Kucab, Jill E., et al.
Publicado: (2015)

Selective targeting p53(WT) lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA
por: Lu, W, et al.
Publicado: (2017)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Novel WT1 Missense Mutations in Han Chinese Women with Premature Ovarian Failure
por: Wang, Huidan, et al.
Publicado: (2015)

Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
por: Sliheet, Elyssa, et al.
Publicado: (2021)

Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission
por: Manning-Geist, Beryl L., et al.
Publicado: (2023)

Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53‐associated features
por: Benor, Gal, et al.
Publicado: (2020)

WT1 peptide analogue WT1-126Y enhances leukemia lysis
por: Alqudaihi, Ghofran, et al.
Publicado: (2014)

WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia
por: Bordin, Fulvio, et al.
Publicado: (2018)

LncRNA WT1-AS up-regulates p53 to inhibit the proliferation of cervical squamous carcinoma cells
por: Zhang, Yunxia, et al.
Publicado: (2019)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

Prognostic Impact of WT-1 Gene Expression in Egyptian Children with Acute Lymphoblastic Leukemia
por: Hagag, Adel A, et al.
Publicado: (2016)

WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma
por: Li, Bing-Qi, et al.
Publicado: (2017)

Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS
por: Rautenberg, Christina, et al.
Publicado: (2019)

Isolating $Wt$ production at the LHC
por: White, Chris D., et al.
Publicado: (2009)

CXCR3 Signaling in BRAF(WT) Melanoma Increases IL-8 Expression and Tumorigenicity
por: Jenkins, Molly H., et al.
Publicado: (2015)

WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
por: Lv, Long, et al.
Publicado: (2015)

Fabrication and wear behaviour of Mg-3wt.%Al-x wt. % SiC composites
por: Jayasathyakawin, S., et al.
Publicado: (2023)

Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
por: Niwa, K., et al.
Publicado: (1994)

Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma
por: Chen, Lihong, et al.
Publicado: (2012)

Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1
por: Das, Andrew B., et al.
Publicado: (2019)

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
por: Azmi, Asfar S., et al.
Publicado: (2011)

Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways
por: Lyu, Y, et al.
Publicado: (2017)

lncRNA DDGC participates in premature ovarian insufficiency through regulating RAD51 and WT1
por: Li, Duan, et al.
Publicado: (2021)

Application of Bioinformatics Analysis to Identify Important Pathways and Hub Genes in Ovarian Cancer Affected by WT1
por: Meng, Kai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4196rn1dqiuk3cph055aeuneb7